BNTX Stock Analysis: Buy, Sell, or Hold?
BNTX - BioNTech SE American Depositary Share
$116.57
5.68 (5.12%)
▲
5d:
+25.22%
30d:
+26.62%
90d:
+28.2%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 04, 2026
0d
Get Alerted When BNTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: BNTX is 15.8% above its trading range ($100.67). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: BNTX is 15.8% above its trading range ($100.67). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: BNTX is currently trading at $116.57, which is considered extended relative to its 30-day fair value range of $87.48 to $100.67.
Technical Outlook: Technically, BNTX is in a uptrend. Immediate support is located at $90.52, while resistance sits at $120.33. The stock is showing strong short-term momentum, up 5.1% recently.
Market Sentiment: BNTX scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BNTX is in a uptrend. Immediate support is located at $90.52, while resistance sits at $120.33. The stock is showing strong short-term momentum, up 5.1% recently.
Market Sentiment: BNTX scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$87.48 -
$100.67
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
15.8%
All Signals
- BEARISH: Price significantly overextended (+15.8% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.1%)
- NEUTRAL: Near Wall St target ($121.68)
- WARNING: Composite score 41/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$87.48 -
$100.67
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$90.52
Resistance Level
$120.33
Current Trend
Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-23.98
Wall Street Target
$121.68
(+4.4%)
Revenue Growth (YoY)
-59.5%
Earnings Growth (YoY)
-43.2%
Profit Margin
-63.6%
Share & Embed Analysis
Last updated: August 23, 2026 3:39 PM ET
Data refreshes hourly during market hours. Next update: 4:39 PM
Data refreshes hourly during market hours. Next update: 4:39 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BNTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Sierk Poetting
SELL
50000 shares
2026-04-22
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 33 SELL |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$49 | 39 SELL |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 26 SELL |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$840 | 34 SELL |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$281 | 55 HOLD |
